Skip to Content

Ozanimod Dosage

Medically reviewed by Drugs.com. Last updated on Aug 10, 2020.

Applies to the following strengths: 0.23 mg-0.46 mg; 0.92 mg; 0.23 mg-0.46 mg-0.92 mg

Usual Adult Dose for Multiple Sclerosis

DOSE TITRATION REGIMEN:
-Days 1 through 4: 0.23 mg orally once a day
-Days 5 through 7: 0.46 mg orally once daily
-Day 8 and thereafter: 0.92 mg orally once a day
MAINTENANCE DOSE: 0.92 mg orally once daily starting on Day 8

Use: For the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Not recommended.

Dose Adjustments

REINITIATION OF THERAPY AFTER INTERRUPTION:
-If a dose is missed during the first 2 weeks of therapy, reinitiate therapy using the titration regimen.
-If a dose is missed after the first 2 weeks of therapy, continue with the dosing as planned.

Precautions

CONTRAINDICATIONS:
-Patients, who in the last 6 months, have experienced a myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure
-Patients who have the presence of Mobitz type II second-degree or third degree atrioventricular (AV) block, sick sinus syndrome, or sinoatrial block, unless the patient has a functioning pacemaker
-Patients who have severe untreated sleep apnea
-Patients who are taking a monoamine oxidase (MAO) inhibitor

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Swallow capsules whole; do not divide, chew, or crush.
-This drug may be administered with or without food.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).

Monitoring:
Before initiation of therapy, assess the following:
-Delay therapy in patients with an active infection until the infection is resolved.
-Complete blood count (CBC)
-Obtain a recent (i.e., within the last 6 months or after discontinuation of prior MS therapy) CBC, including lymphocyte.
-Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present.
-In patients with preexisting conditions, advice from a cardiologist should be sought.
-Obtain recent (i.e., within the last 6 months) transaminase and bilirubin levels.
-In patients with a history of uveitis or macular edema, obtain an evaluation of the fundus, including the macula.
-If patients are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating therapy with this drug.
-Determine if patients are taking drugs that could slow heart rate or atrioventricular conduction.
-Test patients for antibodies to varicella zoster virus (VZV) before initiating this drug; VZV vaccination of antibody-negative patients is recommended prior to commencing therapy with this drug.
-If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of this drug.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.